AI Article Synopsis

  • Coccidioidomycosis is a fungal infection predominantly found in the southwestern U.S., and this study analyzed its occurrence among patients receiving TNF inhibitors (TNFIs) for inflammatory conditions over a seven-year period.
  • Out of 1770 patients treated with TNFIs, 49 (2.8%) developed coccidioidomycosis, with most cases being pulmonary infections and primarily impacting White males.
  • The study found no significant difference in infection rates based on specific TNFI types, and notable that patients with inflammatory bowel disease (IBD) were more likely to experience extrapulmonary infection.

Article Abstract

Unlabelled: Coccidioides fungi are found primarily in the southwestern United States and are the cause of coccidioidomycosis. Tumor necrosis factor α inhibitors (TNFIs) are therapies for autoimmune and inflammatory conditions; their association with coccidioidomycosis is not well characterized. We aimed to determine the prevalence and characteristics of coccidioidomycosis among TNFI recipients with different inflammatory disorders at a tertiary care center. We retrospectively reviewed the electronic health records of patients at our institution from April 4, 2010 to December 17, 2017, who received TNFIs (infliximab, etanercept, adalimumab, certolizumab pegol, or golimumab) and had positive culture, pathologic, and/or serologic results for coccidioidomycosis. Among 1770 patients identified who received TNFIs, 49 (2.8%) had proven or probable coccidioidomycosis. Of these 49, 28 (57%) were men, 47 (96%) were White, and 42 (86%) had pulmonary coccidioidomycosis. The most common TNFIs used were adalimumab, infliximab, and etanercept. Coccidioidomycosis was identified in 25 of 794 patients with rheumatologic disorders (3.1%), 18 of 783 patients with inflammatory bowel disease (IBD) (2.3%), and six of 193 patients with dermatologic disorders (3.1%) (P = .34). There was no difference in coccidioidal infections among recipients of any particular TNFI agents. A minority of patients (7/49, 14%) had an extrapulmonary infection, and the majority of these (6/7) had IBD. Our study shows a low prevalence of coccidioidomycosis in TNFI recipients, even within the Coccidioides-endemic area. Persons with IBD were disproportionately represented among those with extrapulmonary coccidioidomycosis. Treatment with azoles was effective.

Lay Summary: Among 1770 patients who received tumor necrosis factor α inhibitors, 49 (2.8%) had newly acquired coccidioidomycosis over a 7-year period. Dissemination occurred in 14.3%, but disproportionately among those with underlying inflammatory bowel disease. All patients recovered with medical management.

Download full-text PDF

Source
http://dx.doi.org/10.1093/mmy/myaa109DOI Listing

Publication Analysis

Top Keywords

tumor necrosis
12
necrosis factor
12
factor inhibitors
12
coccidioidomycosis
11
patients inflammatory
8
inflammatory disorders
8
coccidioidomycosis tnfi
8
tnfi recipients
8
patients
8
received tnfis
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!